journal article·2013-10

The performance of an orthosilicic acid-releasing silica gel fiber fleece in wound healing

Vera Grotheer, Maria Goergens, Paul C. Fuchs, Sebastian Dunda, Norbert Pallua, Joachim Windolf, Christoph V. Suschek

Biomaterials· Volume 34· Issue 30
Publisher page

Abstract

In the present work, we have examined the impact of an inorganic orthosilicic acid-releasing spun fiber fleece (SIFIB) on wound closure in a porcine wound model in vivo as well as on wound healing-relevant parameters in vitro. In vivo SIFIB was completely bio-degradable and had no negative effects on wound closure or the wound healing process. In the in vitro experiments, SIFIB had no negative effects on proliferation of human skin fibroblast (FB) and endothelial cell (EC) cultures but strongly retarded the growth of the human monocyte cell line THP-1, and effectively inhibited human skin keratinocyte (KC) proliferation, which based on significantly enhanced KC differentiation. Furthermore, SIFIB exhibited strong anti-inflammatory properties, which based on SIFIB-dependent inhibition of expression and activity of NF-кB and/or concomitant enhanced expression of IкB, a NF-кB-inhibiting protein. Additionally, SIFIB significantly inhibited TGFβ-induced fibroblast differentiation and collagen synthesis as well as effectively reduced TGF-β synthesis of activated fibroblasts. We have demonstrated wound healing-relevant biological activities of a silica-based bio-degradable inorganic material, which might represent a new therapeutic tool in the treatment of chronic wounds.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Wound Healing and Treatments · Periodontal Regeneration and Treatments · Corneal Surgery and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (57)

Show source-provided references
1. Growth factors and wound healing: part II. Role in normal and chronic wound healing10.1016/S0002-9610(05)80589-6 ↗
2. Physiology of the chronic wound10.1016/S0094-1298(20)32468-8 ↗
3. The impact of the pH value on skin integrity and cutaneous wound healing10.1111/j.1468-3083.2009.03413.x ↗
4. Targeting matrix metalloproteases to improve cutaneous wound healing10.1517/14728222.10.1.143 ↗
5. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing
7. Perspective article: growth factors and cytokines in wound healing10.1111/j.1524-475X.2008.00410.x ↗
8. Refractory ulcers: the role of tumor necrosis factor–α10.1016/j.jaad.2009.08.004 ↗
9. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers10.1046/j.1524-475x.2000.00013.x ↗
10. Proteinases, their inhibitors, and cytokine profiles in acute wound fluid10.1111/j.1524-475X.2000.00392.x ↗
11. Levels of tumor necrosis factor-alpha and soluble TNF receptors in chronic venous leg ulcers – correlations to healing status10.1046/j.1523-1747.1998.00113.x ↗
12. Biochemical analysis of acute and chronic wound environments10.1046/j.1524-475X.1996.40307.x ↗
13. Nanocrystalline silver, gelatinases and the clinical implications10.1016/j.burns.2010.01.010 ↗
14. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors10.1046/j.1524-475X.1999.00442.x ↗
15. Tumor necrosis factor-alpha (TNF-α) is a therapeutic target for impaired cutaneous wound healing10.1111/j.1524-475X.2011.00748.x ↗
16. Blocking interleukin-1β in acute and chronic autoinflammatory diseases10.1111/j.1365-2796.2010.02313.x ↗
17. Matrix metalloproteinases in repair10.1046/j.1524-475X.1999.00423.x ↗
18. Differential expression of matrix metalloproteinases during impaired wound healing of the diabetes mouse10.1046/j.1523-1747.2002.01779.x ↗
19. The myofibroblast: a key cell for wound healing and fibrocontractive diseases
20. The myofibroblast in wound healing and fibrocontractive diseases10.1002/path.1427 ↗
21. Importance of moisture balance at the wound-dressing interface10.12968/jowc.2003.12.4.26484 ↗
22. Hydrogel wound dressings: where do we stand in 2003?
23. The effect of wound dressings on the pH stability of fluids10.12968/jowc.2012.21.2.88 ↗
24. Silver and nanoparticles of silver in wound dressings: a review of efficacy and safety10.12968/jowc.2011.20.11.543 ↗
25. Wound dressing with sustained anti-microbial capability10.1002/(SICI)1097-4636(2000)53:1<8::AID-JBM2>3.0.CO;2-3 ↗
26. Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination10.1159/000318267 ↗
27. Biodegradable silica fibers from sols10.1023/A:1008651505705 ↗
28. Porcine wound models for skin substitution and burn treatment10.1016/S0142-9612(03)00502-7 ↗
29. Ultraviolet A1 radiation induces nitric oxide synthase-2 expression in human skin endothelial cells in the absence of proinflammatory cytokines10.1046/j.0022-202x.2001.01502.x ↗
30. Nitric oxide fully protects against UVA-induced apoptosis in tight correlation with Bcl-2 up-regulation10.1074/jbc.274.10.6130 ↗
31. Biphasic effect of exogenous nitric oxide on proliferation and differentiation in skin derived keratinocytes but not fibroblasts10.1046/j.1523-1747.1998.00268.x ↗
32. Treatment of nonhealing ulcers with allografts10.1016/j.clindermatol.2004.07.020 ↗
33. Extent of iron pick-up in deforoxamine-coupled polyurethane materials for therapy of chronic wounds10.1016/j.biomaterials.2005.03.015 ↗
34. In vitro inhibition of human neutrophil elastase by oleic acid albumin formulations from derivatized cotton wound dressings10.1016/j.ijpharm.2004.06.003 ↗
35. Influence of selected wound dressings on PMN elastase in chronic wound fluid and their antioxidative potential in vitro10.1016/j.biomaterials.2005.04.030 ↗
36. Platelet gel for healing cutaneous chronic wounds10.1016/j.transci.2004.01.004 ↗
37. Walmsley · 2002
38. Interleukin-1, inflammasomes and the skin10.1016/j.ejcb.2010.04.008 ↗
39. Proinflammatory cytokines10.1378/chest.118.2.503 ↗
40. Essential role of IL-6 signaling pathway in keloid pathogenesis10.1272/jnms.74.11 ↗
41. Molecular regulation of B lymphocyte response10.1146/annurev.iy.06.040188.002413 ↗
42. Induction of keratinocyte proliferation and lymphocytic infiltration by in vivo introduction of the IL-6 gene into keratinocytes and possibility of keratinocyte gene therapy for inflammatory skin diseases using IL-6 mutant genes10.4049/jimmunol.161.10.5633 ↗
43. Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity10.1186/1475-2840-9-50 ↗
44. Bioactive interleukin-8 is expressed in wounds and enhances wound healing10.1006/jsre.2000.5892 ↗
45. Interleukin-8 levels and activity in delayed-healing human thermal wounds10.1046/j.1524-475x.2000.00216.x ↗
46. Signalling, inflammation and arthritis10.1093/rheumatology/kem298 ↗
47. Inhibiting NF-κB activation by small molecules as a therapeutic strategy
48. Myofibroblasts and mechano-regulation of connective tissue remodelling10.1038/nrm809 ↗
49. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar
50. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts10.1083/jcb.122.1.103 ↗
51. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia
52. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro10.1073/pnas.83.12.4167 ↗
53. Negative regulation of nuclear factor-kappaB activation and function by glucocorticoids10.1677/jme.0.0280069 ↗
54. Administration of prednisolone phosphate-liposomes reduces wound contraction in a rat partial-thickness wound model10.1111/j.1743-6109.2006.00167.x ↗
55. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases10.1046/j.1365-2133.2002.04949.x ↗
56. Regulation of involucrin gene expression by retinoic acid and glucocorticoids
57. Glucocorticoids and differentiation